Evidence map›Paper›PMID 38530613›Full record

ArticleInterdisciplinary sciences, computational life sciences2024

DOTAD: A Database of Therapeutic Antibody Developability.

Wenzhen Li, Hongyan Lin, Ziru Huang, Shiyang Xie, Yuwei Zhou, Rong Gong, Qianhu Jiang, ChangCheng Xiang, Jian Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Interdisciplinary sciences, computational life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenzhen Li *School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Hongyan Lin *School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Ziru HuangSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Shiyang XieSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Yuwei ZhouSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Rong GongSchool of Computer Science and Technology, Aba Teachers University, Aba, 623002, China.
Qianhu JiangSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
ChangCheng XiangSchool of Computer Science and Technology, Aba Teachers University, Aba, 623002, China. 19999607@abtu.edu.cn.
Jian HuangSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China. hj@uestc.edu.cn.ORCID http://orcid.org/0000-0003-3282-8892

Funding

National Natural Science Foundation of China 62071099
6 · The paper itself

Abstract

The development of therapeutic antibodies is an important aspect of new drug discovery pipelines. The assessment of an antibody's developability-its suitability for large-scale production and therapeutic use-is a particularly important step in this process. Given that experimental assays to assess antibody developability in large scale are expensive and time-consuming, computational methods have been a more efficient alternative. However, the antibody research community faces significant challenges due to the scarcity of readily accessible data on antibody developability, which is essential for training and validating computational models. To address this gap, DOTAD (Database Of Therapeutic Antibody Developability) has been built as the first database dedicated exclusively to the curation of therapeutic antibody developability information. DOTAD aggregates all available therapeutic antibody sequence data along with various developability metrics from the scientific literature, offering researchers a robust platform for data storage, retrieval, exploration, and downloading. In addition to serving as a comprehensive repository, DOTAD enhances its utility by integrating a web-based interface that features state-of-the-art tools for the assessment of antibody developability. This ensures that users not only have access to critical data but also have the convenience of analyzing and interpreting this information. The DOTAD database represents a valuable resource for the scientific community, facilitating the advancement of therapeutic antibody research. It is freely accessible at http://i.uestc.edu.cn/DOTAD/ , providing an open data platform that supports the continuous growth and evolution of computational methods in the field of antibody development.

Indexed as

AntibodiesDatabases, FactualHumansUser-Computer InterfaceAntibodiesAntibody developmentDatabaseDevelopabilityTherapeutic antibody

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.